Microba Life Sciences Limited (ASX:MAP)

Market Cap	48.72M -54.7%
Revenue (ttm)	14.90M -11.8%
Net Income	-19.75M
EPS	-0.04
Shares Out	608.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	89,981
Average Volume	171,340
Open	0.0770
Previous Close	0.0800
Day's Range	0.0770 - 0.0800
52-Week Range	0.0690 - 0.2300
Beta	2.37
RSI	43.82
Earnings Date	Apr 20, 2026

About Microba Life Sciences

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MAP

Financial Performance

In fiscal year 2025, Microba Life Sciences's revenue was 15.67 million, an increase of 29.60% compared to the previous year's 12.09 million. Losses were -14.94 million, -25.07% less than in 2024.